Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 2/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SI | P14410 | 2/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2336675 | 0.86 | LMNA (0.59) | LMNAKMT2ARAB9AALDH1A1MGAM | |
| SCHEMBL2330999 | 0.79 | LMNA (0.45) | LMNAKMT2ARAB9AALDH1A1MGAM | |
| SCHEMBL4145138 | 0.72 | SMN1; SMN2 (0.46) | LMNAKMT2ARAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2332245 | 0.71 | MAPT (0.57) | LMNAKMT2ARAB9AALDH1A1MGAM | |
| SCHEMBL3630523 | 0.70 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2NPC1P2RX7MAPT | |
| SCHEMBL2334305 | 0.69 | LMNA (0.59) | LMNAKMT2ARAB9AALDH1A1MGAM | |
| SCHEMBL2331420 | 0.67 | LMNA (0.60) | LMNAKMT2ARAB9AALDH1A1MGAM | |
| SCHEMBL22259649 | 0.65 | HPGD (0.53) | LMNAALDH1A1SMN1; SMN2MAPTPOLB | |
| Dimethylformamide SCHEMBL28746208 | 0.65 | L3MBTL1 (0.45) | LMNAKMT2ARAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4130206 | 0.64 | HSD17B10 (0.52) | KMT2ARAB9AALDH1A1SMN1; SMN2MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2534155-B1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENT MANAGEMENT PTY LTD (AU) | 2018-04-11 | — | — | EP | disclosed |
| US-9540387-B2 | Substituted imidazo[1,2-d]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2017-01-10 | — | — | US | disclosed |
| US-20160046642-A1 | Compounds for Treating Respiratory Syncytial Virus Infections | BIOTA SCIENT MANAGEMENT (AU) | 2016-02-18 | — | — | US | disclosed |
| US-9163029-B2 | Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20140051697-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-8604034-B2 | Substituted imidazo[1,2-α]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus (RSV) infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2013-12-10 | — | — | US | disclosed |
| EP-2534155-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | Biota Scientific Management Pty Ltd (AU) | 2012-12-19 | — | — | EP | disclosed |
| US-20110207728-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2011-08-25 | — | — | US | disclosed |
| WO-2011094823-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207728-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | FURIN, SQOR, SUCNR1 | LMNA 1790/4885KMT2A 3375/4885RAB9A 1457/4885 |
| US-20160046642-A1 | Compounds for Treating Respiratory Syncytial Virus Infections | FURIN, SQOR, SUCNR1 | LMNA 1790/4885KMT2A 3375/4885RAB9A 1457/4885 |
| US-20140051697-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | FURIN, SQOR, SUCNR1 | LMNA 1790/4885KMT2A 3375/4885RAB9A 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.